ATE162801T1 - Tnf(tumor necrosis factor)-inhibitor und verfahren zur herstellung - Google Patents

Tnf(tumor necrosis factor)-inhibitor und verfahren zur herstellung

Info

Publication number
ATE162801T1
ATE162801T1 AT90113673T AT90113673T ATE162801T1 AT E162801 T1 ATE162801 T1 AT E162801T1 AT 90113673 T AT90113673 T AT 90113673T AT 90113673 T AT90113673 T AT 90113673T AT E162801 T1 ATE162801 T1 AT E162801T1
Authority
AT
Austria
Prior art keywords
tnf
inhibitor
40kda
necrosis factor
tumor necrosis
Prior art date
Application number
AT90113673T
Other languages
English (en)
Inventor
Michael T Brewer
Karin K Hale
Michael W King
Tadahiko Kohno
Charles Squires
Robert C Thompson
Rebecca W Vanderslice
James Vannice
Original Assignee
Amgen Boulder Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27409520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE162801(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Boulder Inc filed Critical Amgen Boulder Inc
Application granted granted Critical
Publication of ATE162801T1 publication Critical patent/ATE162801T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT90113673T 1989-07-18 1990-07-17 Tnf(tumor necrosis factor)-inhibitor und verfahren zur herstellung ATE162801T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38108089A 1989-07-18 1989-07-18
US45032989A 1989-12-11 1989-12-11
US47966190A 1990-02-07 1990-02-07

Publications (1)

Publication Number Publication Date
ATE162801T1 true ATE162801T1 (de) 1998-02-15

Family

ID=27409520

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90113673T ATE162801T1 (de) 1989-07-18 1990-07-17 Tnf(tumor necrosis factor)-inhibitor und verfahren zur herstellung

Country Status (20)

Country Link
US (1) US6541620B1 (de)
EP (2) EP0790306A3 (de)
JP (1) JPH03163099A (de)
KR (1) KR100230156B1 (de)
AT (1) ATE162801T1 (de)
AU (1) AU647397B2 (de)
CA (1) CA2021369A1 (de)
DE (1) DE69031997T2 (de)
DK (1) DK0422339T3 (de)
ES (1) ES2116970T3 (de)
FI (1) FI114398B (de)
GR (1) GR3026416T3 (de)
IE (2) IE990595A1 (de)
IL (2) IL95031A (de)
NO (1) NO306728B1 (de)
NZ (1) NZ234499A (de)
PL (1) PL168844B1 (de)
PT (1) PT94754B (de)
SG (1) SG55131A1 (de)
TW (1) TW206234B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
EP0939121B2 (de) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5304634A (en) * 1990-10-12 1994-04-19 Hoechst Aktiengesellschaft Inhibitors for the formation of tumor necrosis factor
GB9027917D0 (en) 1990-12-21 1991-02-13 Ici Plc Expression systems
ES2145744T5 (es) * 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
ATE242322T1 (de) * 1992-03-30 2003-06-15 Immunex Corp Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
ATE188610T1 (de) * 1992-04-30 2000-01-15 Amgen Inc Methoden zur behandlung von interleukin- 1 und - tumor - nekrose - faktor - verursachten krankheiten
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
IT1276040B1 (it) * 1993-07-27 1997-10-24 Angelini Francesco Ist Ricerca Uso della benzidamina nel trattamento di stati patologici causati dal tnf
SK288144B6 (sk) 1996-02-09 2013-12-02 Amgen, Inc. Pharmaceutical composition and its use for treating inflammatory diseases
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ES2312179T3 (es) 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
WO1998024463A2 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
DK1032575T3 (da) * 1997-09-05 2003-10-20 Glaxo Group Ltd 2,3-diaryl-pyrazol(1,5-b)pyridazinderivater, deres fremstilling og anvendelse som cyclooxygenase 2 (COX-2) inhibitor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
JP2003525612A (ja) 2000-03-02 2003-09-02 ゼンコー ＴＮＦ−α関連障害の処置のための変種ＴＮＦ−αタンパク質の設計および発見
TWI322154B (en) 2000-03-16 2010-03-21 Amgen Inc Il-17 receptor like molecules and uses thereof
US7879448B2 (en) * 2000-07-11 2011-02-01 Guardian Industires Corp. Coated article with low-E coating including IR reflecting layer(s) and corresponding method
CA2421588C (en) 2000-09-05 2010-01-26 Amgen Inc. Tnf receptor-like molecules and uses thereof
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
EP2295081B1 (de) 2001-06-26 2018-10-31 Amgen Inc. Antikörper gegen OPGL
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
AU2004287431B2 (en) 2003-10-27 2010-03-11 Amgen Inc. Compositions and methods to modulate an immune response to an immunogenic therapeutic agent
US7785834B2 (en) * 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
WO2007058894A2 (en) * 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US9052304B2 (en) 2009-03-13 2015-06-09 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
CA2944605C (en) 2014-03-31 2023-10-17 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IN150740B (de) 1978-11-24 1982-12-04 Hoffmann La Roche
US4560649A (en) 1981-10-15 1985-12-24 Cornell Research Foundation Assaying for hLH or hCG with immobilized hormone receptors
JPH0751511B2 (ja) 1982-03-15 1995-06-05 味の素株式会社 インターロイキン２を含有してなる癌治療剤
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4966888A (en) 1985-07-08 1990-10-30 Cornell Research Foundation, Inc. hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4578335A (en) 1984-05-21 1986-03-25 Immunex Corporation Interleukin 2 receptor
CA1339269C (en) 1984-05-21 1997-08-12 Douglas P. Cerretti Purification of and cloning of the gene for interleukin-2 receptor
US4675285A (en) 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2524586B2 (ja) 1985-06-26 1996-08-14 シタス コーポレイション ポリマ−接合を利用する医薬組成物用蛋白質の可溶化
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
CA1283046C (en) 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
IN165717B (de) 1986-08-07 1989-12-23 Battelle Memorial Institute
US4931544A (en) 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
IL80005A (en) 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US5512544A (en) 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
GB8806339D0 (en) 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5359037A (en) 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
US5811261A (en) 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US5162430A (en) 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3920282A1 (de) 1989-06-21 1991-01-03 Boehringer Ingelheim Int Tnf-rezeptor, tnf bindende proteine und dafuer kodierende dnas
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DE3913101A1 (de) 1989-04-21 1990-10-31 Boehringer Ingelheim Int Tnf-(alpha) bindende proteine und dafuer kodierende dnas
DK0393438T3 (da) * 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
JPH03164179A (ja) * 1989-04-21 1991-07-16 Boehringer Ingelheim Internatl Gmbh Ｔｎｆレセプター、ｔｎｆ結合たん白質およびこれらをコードするｄｎａ
DE3922089A1 (de) * 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
AU636608B2 (en) * 1989-05-18 1993-05-06 Yeda Research And Development Co. Ltd. Tumor necrosis factor binding protein II, it's purification and antibodies thereto
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
WO1991003553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation TUMOR NECROSIS FACTOR-α AND -β RECEPTORS
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
AU642938B2 (en) 1989-12-13 1993-11-04 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein 1 (TBP-1)
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
GB2246569A (en) 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
AU657483B2 (en) 1990-07-20 1995-03-16 Pharmacia Ab Heterobifunctional reagents and conjugates with oxaalkylene units for amphiphilic bridge structures
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2145744T5 (es) 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
CA2100671C (en) 1991-02-27 1999-02-02 James S. Huston Serine rich peptide linkers
ATE240740T1 (de) * 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications

Also Published As

Publication number Publication date
DE69031997T2 (de) 1998-05-14
PT94754A (pt) 1991-03-20
AU647397B2 (en) 1994-03-24
US6541620B1 (en) 2003-04-01
PL168844B1 (pl) 1996-04-30
NO306728B1 (no) 1999-12-13
PT94754B (pt) 1997-04-30
EP0790306A3 (de) 1998-07-01
CA2021369A1 (en) 1991-01-19
JPH03163099A (ja) 1991-07-15
IL131281A0 (en) 2001-01-28
HK1014539A1 (en) 1999-09-30
AU5897690A (en) 1991-01-24
IL95031A (en) 2007-03-08
EP0790306A2 (de) 1997-08-20
FI114398B (fi) 2004-10-15
DK0422339T3 (da) 1998-09-23
NO306728B3 (de) 2003-02-17
EP0422339B1 (de) 1998-01-28
IE990595A1 (en) 2000-11-15
SG55131A1 (en) 1998-12-21
ES2116970T3 (es) 1998-08-01
GR3026416T3 (en) 1998-06-30
EP0422339A1 (de) 1991-04-17
DE69031997D1 (de) 1998-03-05
KR100230156B1 (ko) 1999-11-15
KR910015309A (ko) 1991-09-30
NO903192D0 (no) 1990-07-17
FI903591A0 (fi) 1990-07-16
PL286089A1 (en) 1991-07-29
IL95031A0 (en) 1991-06-10
NO903192L (no) 1991-01-21
IE902608A1 (en) 1991-02-27
TW206234B (de) 1993-05-21
NZ234499A (en) 1992-08-26

Similar Documents

Publication Publication Date Title
ATE162801T1 (de) Tnf(tumor necrosis factor)-inhibitor und verfahren zur herstellung
IL90423A (en) Interleukin-1 inhibitors methods for producing them pharmaceutical compositions containing them isolated DNA sequences encoding interleukin-1 inhibitors and host cells and vectors containing them
DE59900115D1 (de) Verfahren zur Herstellung von (Meth)Acrylatestern von Organosiloxanpolyolen
ATE298800T1 (de) Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein
JPS6429362A (en) 3-demethylmevalonic acid derivative
DE69422064D1 (de) Verfahren zur Herstellung von optischaktiven 4-Halo-3-hydroxybuttersäure-Estern
ATE159720T1 (de) Saccharinderivate zur verwendung als proteolytische enzyminhibitoren sowie verfahren zur herstellung
ITMI912432A1 (it) Procedimento e apparecchiatura per la fermentazione di amminoacidi
ATE184917T1 (de) Rekombinante methode und wirt zur herstellung von xylitol
DE59309649D1 (de) Substituierte Cyclohexan-Derivate zur Behandlung von Krankheiten
DE69705192D1 (de) Verfahren zur Herstellung von (Meth)acrylsäure
DE59404310D1 (de) Verfahren zur Herstellung von Alkoxy-carbonsäureestern
ATE135703T1 (de) Substituierte 2-imidazoline und verfahren zur herstellung sowie deren verwendung
ATE37873T1 (de) Verfahren zur herstellung optisch aktiver 1,4dihydropyridine.
DE69624236D1 (de) Ausgewählte lösliche ester von indolcarbazolen die hydroxyl enthalten
DE3863206D1 (de) (vinylphenyl)phenylmethan sowie verfahren zur herstellung von (benzoylphenyl)propionsaeure.
DE59705359D1 (de) Verfahren zur Herstellung von 2-Cyanoethyl-phosphinsäureestern
FI945353A7 (fi) Entsymaattinen menetelmä (S)-6-metoksyyli-alfa-metyyli-2-naftaleenieti kkahapon valmistamiseksi
ATE110720T1 (de) Verfahren zur herstellung von 2-mercapto-4-methyl-1,3-thiazol-5-yl-essigsäure und deren ester.
ATE122676T1 (de) Verfahren zur herstellung von 1,3-substituiertem tetrahydro-1h-thieno-(3,4-d>-imidazol-2(3h)-on- - yliden-pentansäureester.
DE59003785D1 (de) 3-substituierte 2-Hydroxy-3-formylpropionsäureester, Verfahren zu deren Herstellung sowie deren Verwendung zur Herstellung von 3-substituierten 3-Formyl-acrylsäurereestern.
DE59600655D1 (de) Verfahren zur Herstellung von 2-Aryl-2-chlormalonsäurediestern
DE59403768D1 (de) Verfahren zur Herstellung von 2-Cyanoacetoxy-propionsäureestern
ITBO960037A0 (it) Composizione e procedimento per la sterilizzazione di substrati di coltura
ATE43918T1 (de) Verfahren zur fokussierung eines optischen abbildungssystems sowie einrichtung zur durchfuehrung des verfahrens.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
RZN Patent revoked